GYNETNCT04652076
GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
Minor Trial completed Show 4 more changesShow less
- Trial status changed: Unknown → Active, Not Recruiting
- Study completion date changed from estimate of Dec 31, 2026 to Nov 16, 2026
- Study completion pushed from Jul 30, 2026 to Dec 31, 2026
- Enrollment target: estimated 240 to confirmed 238
Notable Eligibility criteria expanded, about 30 words Show 4 more changesShow less
- Study completion date: Jul 30, 2026 to Dec 31, 2026
- Secondary endpoints: details revised at 1 of 11 entries
- Site details revised at 2 of 15 sites
- Collaborators: details revised at 1 of 2 entries
- Minor Changed Registry marked status Unknown; last known: Active, Not Recruiting
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 15 of 15 sites
- Notable Primary completion date: Oct 30, 2024 to Oct 30, 2025
- Study completion date: Jul 30, 2025 to Jul 30, 2026
Show 7 earlier versionsHide 7 earlier versions
- Notable Primary completion date: Oct 25, 2023 to Oct 30, 2024
- Study completion date: Nov 25, 2024 to Jul 30, 2025
- Notable Primary completion date: Oct 25, 2022 to Oct 25, 2023
- Study sites: 12 to 15
- Minor Site contacts updated at 1 of 12 sitesv6
- Notable Eligibility criteria expanded, about 43 wordsv5
- Notable Primary completion date: Oct 25, 2021 to Oct 25, 2022
- Study sites: 6 to 12
- Notable Eligibility criteria expanded, about 40 words
- Study sites: 4 to 6
- Primary completion date: Jun 25, 2021 to Oct 25, 2021
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria expanded, about 50 words
- Study sites: 0 to 4
- Start date changed from estimate of Nov 25, 2020 to Dec 14, 2020
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Standard Chemotherapy will be adminitred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
Experimental double combination \[Standard Chemotherapy +NP137\] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
Experimental double combination \[Pembrolizumab +NP137\] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
Experimental triple combination \[Pembrolizumab+ Standard Chemotherapy + NP137\] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
Drugs: NP137, Pembrolizumab, Paclitaxel, Carboplatin
Sites
15 sites in 1 country